يعرض 1 - 20 نتائج من 2,881 نتيجة بحث عن '"ugt"', وقت الاستعلام: 0.55s تنقيح النتائج
  1. 1
    Dissertation/ Thesis
  2. 2
    Academic Journal
  3. 3
    Academic Journal
  4. 4
    Dissertation/ Thesis
  5. 5
    Academic Journal
  6. 6
    Academic Journal
  7. 7
    Academic Journal
  8. 8
    Academic Journal
  9. 9
    Academic Journal
  10. 10
    Academic Journal
  11. 11
    Academic Journal
  12. 12
    Academic Journal
  13. 13
    Academic Journal
  14. 14
    Academic Journal
  15. 15
    Academic Journal
  16. 16
  17. 17
  18. 18
    Academic Journal

    المصدر: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 69, № 5 (2024); 65-74 ; Российский вестник перинатологии и педиатрии; Том 69, № 5 (2024); 65-74 ; 2500-2228 ; 1027-4065

    وصف الملف: application/pdf

    Relation: https://www.ped-perinatology.ru/jour/article/view/2067/1533; Pal A., Kaskel F. History of Nephrotic Syndrome and Evolution of its Treatment. Front Pediatr 2016; 4: 56. DOI:10.3389/fped.2016.00056; Cameron J.S., Hicks J. The origins and development of the concept of a “nephrotic syndrome”. Am J Nephrol 2002; 22(2–3): 240–247. DOI:10.1159/000063768; Hahn D., Samuel S.M., Willis N.S., Craig J.C., Hobson E.M. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 2020; 2020(8): CD001533. DOI:10.1002/14651858.CD001533.pub6; Морозов С.Л., Курсова Т.С., Петросян Э.К., Пирузиева О.Р., Длин В.В. Микофенолата мофетил в терапии первичного нефротического синдрома у детей. Российский вестник перинатологии и педиатрии 2023; 68(2): 22–28.; Banaszak B., Banaszak P. The increasing incidence of initial steroid resistance in childhood nephrotic syndrome. Pediatr Nephrol 2012; 27(6): 927–932. DOI:10.1007/s00467–011–2083–7; Морозов С.Л., Длин В.В., Садыков А.Р., Воронкова А.С., Сухоруков В.С. Механизмы резистентности к иммуносупрессивной терапии у пациентов с нефротическим синдромом. Российский вестник перинатологии и педиатрии 2017; 62(4): 19–24.; Filler G., Alvarez-Elías A.C., McIntyre C., Medeiros M. The compelling case for therapeutic drug monitoring of mycophenolate mofetil therapy. Pediatr Nephrol 2017; 32(1): 21–29. DOI:10.1007/s00467–016–3352–2; Lamba V., Sangkuhl K., Sanghavi K., Fish A., Altman R.B., Klein T.E. PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics 2014; 24(1): 73–79. DOI:10.1097/FPC.0000000000000010; McMurray R.W., Harisdangkul V. Mycophenolate mofetil: selective T cell inhibition. Am J Med Sci 2002; 323(4): 194–196. DOI:10.1097/00000441–200204000–00005; Hedstrom L. IMP dehydrogenase: structure, mechanism, and inhibition. Chem Rev 2009; 109(7): 2903–2928. DOI:10.1021/cr900021w; Jonsson C.A., Carlsten H. Mycophenolic acid inhibits inosine 5’-monophosphate dehydrogenase and suppresses immunoglobulin and cytokine production of B cells. Int Immunopharmacol 2003; 3(1): 31–37. DOI:10.1016/s1567–5769(02)00210–2; Betonico G.N., Abudd-Filho M., Goloni-Bertollo E.M., Pavarino-Bertelli E. Pharmacogenetics of mycophenolate mofetil: a promising different approach to tailoring immunosuppression? J Nephrol 2008; 21(4): 503–509.; Michelon H., König J., Durrbach A., Quteineh L., Verstuyft C., Furlan V. et al. SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics 2010; 11(12): 1703–1713. DOI:10.2217/pgs.10.132; Kiberd B.A., Lawen J., Fraser A.D., Keough-Ryan T., Belitsky P. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant 2004; 4(7): 1079–1083. DOI:10.1111/j.1600–6143.2004.00455.x; Na Takuathung M., Sakuludomkan W., Koonrungsesomboon N. The Impact of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid: Systematic Review and Meta-analysis. Clin Pharmacokinet 2021; 60(10): 1291–1302. DOI:10.1007/s40262–021–01037–7; Meng H.Y., Luo Z.H., Hu B., Jin W.L., Yan C.K., Li Z.B. et al. SNPs affecting the clinical outcomes of regularly used immunosuppressants. Pharmacogenomics 2018; 19(5): 495–511. DOI:10.2217/pgs-2017–0182; Joy M.S., Boyette T., Hu Y., Wang J., La M. Effects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritis. Eur J Clin Pharmacol 2010; 66(11): 1119–30. DOI:10.1007/s00228–010–0846-x; Морозов С.Л., Пахомова В.П., Войнова В.Ю. Профиль экспрессии генов, ассоциированных со стероидной зависимостью, у детей с идиопатическим нефротическим синдромом. Практическая медицина 2024; 22(3): 57–62.; Bergan S., Brunet M., Hesselink D.A., Johnson-Davis K.L. Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit 2021; 43(2): 150–200. DOI:10.1097/FTD.0000000000000871; Wang J., Figurski M., Shaw L.M., Burckart G.J. The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice. Transpl Immunol 2008; 19(3–4): 192–196. DOI:10.1016/j.trim.2008.05.009; Rosso Felipe C., de Sandes T.V., Sampaio E.L., Park S.I., Silva H.T., Jr, Medina Pestana J.O. Clinical impact of polymorphisms of transport proteins and enzymes involved in the metabolism of immunosuppressive drugs. Transplant Proc 2009; 41(5): 1441–1455. DOI:10.1016/j.transproceed.2009.03.024; Yap D.Y.H., Tam C.H., Yung S., Wong S., Tang C.S.O., Mok T.M.Y. et al. Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. Nephrol Dial Transplant 2020; 35(5): 810–818. DOI:10.1093/ndt/gfy284; Bernard O., Guillemette C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos 2004; 32(8): 775–778. DOI:10.1124/dmd.32.8.775; Rong Y., Jun H., Kiang T.K.L. Population pharmacokinetics of mycophenolic acid in paediatric patients. Br J Clin Pharmacol 2021; 87(4): 1730–1757. DOI:10.1111/bcp.14590; Djebli N., Picard N., Rérolle J.P., Le Meur Y., Marquet P. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet Genomics 2007; 17(5): 321–330. DOI:10.1097/FPC.0b013e32801430f8

  19. 19
    Academic Journal
  20. 20